Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Idiopathic pulmonary arterial hypertension (IPAH) is defined in the packet as a sporadic form of pulmonary arterial hypertension (PAH) characterized by elevated pulmonary arterial resistance leading to right heart failure. The definition describes IPAH as progressive and potentially fatal, and as not associated with an underlying condition or a family history of PAH. The etiology is stated to be unknown. Synonyms recorded include IPAH, primary pulmonary arterial hypertension and primary pulmonary hypertension. The prevalence record places the condition in the RARE category with an estimate of 1-9 in 1,000,000; the packet does not specify the measure type, population or geography for this estimate. The packet records affected organ systems as cardiovascular and respiratory.
Data assembled from 6 of 12 sources · Last updated Nov 17, 2026, 3:00 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
European rare disease database
The packet's phenotype annotations (16 recorded) carry HPO frequency categories, and they are grouped here by organ system. Respiratory feature: dyspnea is annotated as always present (100%). Cardiovascular features annotated at 80-99% (very frequent) are pulmonary arterial hypertension, elevated pulmonary artery pressure, increased pulmonary vascular resistance, right ventricular hypertrophy and abnormal jugular vein morphology. Cardiovascular and related features annotated at 30-79% (frequent) are edema of the dorsum of the feet, congestive heart failure, ankle swelling, tricuspid regurgitation, heart murmur, chest pain and syncope. Features annotated at 5-29% (occasional) are pedal edema, hemoptysis and palpitations. These annotations are population-level frequency labels and do not describe any individual's course. The packet supplies no age-of-onset categories and no GeneReviews clinical description.
The definition in the packet states that the etiology of IPAH is unknown and that the condition is sporadic and not associated with an underlying condition or a family history of PAH. The packet lists no known genes and no inheritance pattern, so no genetic basis is described here. This reflects what the packet supplies and is not a statement about the genetics of the condition more broadly. No other causes or risk factors are supplied.
The packet contains no diagnostic methods, diagnostic criteria or GeneReviews diagnosis content for this condition, so no testing approach is certified here. The phenotype annotations, including elevated pulmonary artery pressure and increased pulmonary vascular resistance, are descriptive frequency data and are not presented as diagnostic criteria. The packet records no newborn screening information.
The packet's approved-treatment field lists two products with an active FDA market status, both containing epoprostenol and both approved through an NDA reviewed by CDER: VELETRI (epoprostenol), approved 2008-06-27, and FLOLAN (epoprostenol sodium), approved 1995-09-20. The orphan-drug records also include a FLOLAN entry with status APPROVED and the indication 'treatment of primary pulmonary hypertension'. The orphan-drug records further contain entries with status APPROVED for several other agents with indications for pulmonary arterial hypertension, but those agents do not appear in the packet's approved-treatment field, so their approval is not described here beyond that orphan-record status. Several additional agents appear in the orphan-drug records with status DESIGNATED, and one with status WITHDRAWN. Orphan designation is not FDA approval, and only the two epoprostenol products are certified in the approved-treatment field as current FDA-approved options in this packet. The packet supplies no foundational therapies, no GeneReviews management content and no information on care teams, so none is described here.
116 trials found
The packet's definition describes IPAH as progressive and potentially fatal, and describes elevated pulmonary arterial resistance leading to right heart failure. No natural history timeline, survival figures or life expectancy are certified in this packet.
The packet records active ClinicalTrials.gov records for the search term used and supplies ten detailed records. Several concern pulmonary arterial hypertension broadly and may not be limited to the idiopathic form. Examples include NCT07600723, a Phase 4 study of sotatercept in people with PAH in India (Merck Sharp & Dohme LLC; recruiting; start 2026-10-08, completion 2028-04-03); NCT07612657, a Phase 3 study of extended-release tacrolimus in subjects with PAH and functional limitations (VIVUS LLC; not yet recruiting; start 2026-05-29, completion 2029-11-30); NCT07366879, an exercise intervention study in newly diagnosed PAH (Golden Jubilee National Hospital; recruiting; start 2026-04-02, completion 2028-01-01); and NCT03288025, a nutrition and exercise study (The Cleveland Clinic; active, not recruiting; start 2017-09-27, completion 2027-06-30). Other listed records include a Phase 2 xenon MRI study in pulmonary hypertension (NCT04991454), the PVDOMICS pulmonary vascular disease phenomics program (NCT02980887) and an imaging study of fibrotic disease activity in cardiopulmonary disorders (NCT07613099). Trial titles are not claims about the effect of any intervention. The packet's publication digest classifies 188 items, with basic science and preclinical work as the dominant type, and notes the presence of gene therapy, biomarker and recent trial publications.
AI-curated news mentioning idiopathic pulmonary arterial hypertension
Updated Oct 19, 2026
Recent research highlights the potential for partial echocardiographic remission in patients with pulmonary arterial hypertension following treatment with sotatercept. This finding suggests an expansion of treatment goals beyond symptom management.
A study reports sustained improvement in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension following CD19 CAR T-cell therapy over one year. This research highlights the potential of CAR T-cell therapy in treating complex rare diseases.
A recent EUSTAR analysis investigates treatment strategies and outcomes for systemic sclerosis-associated pulmonary arterial hypertension, focusing on different haemodynamic thresholds and risk stratification. This study provides insights that could inform clinical decision-making in managing this complex condition.
A recent Lancet study shows that ralinepag reduced clinical worsening in pulmonary arterial hypertension (PAH) by 55%. Funded by United Therapeutics, the trial highlighted a higher rate of treatment discontinuations due to adverse events compared to placebo.